Kyverna Therapeutics, Inc. KYTX

US Biotechnology

$5.11 ▼ -1.16% ($-0.06)

🔥 High Short Interest 🎢 High Beta 📅 Earnings This Week

Open $5.16

Prev Close $5.17

Day Range $5.00 – $5.29

52W Range $4.50 – $13.67

Market Cap $319.73M

Beta 2.18

EPS (TTM) $-2.94

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-02-08
Shares Out.	61,840,000
Website	kyvernatx.com/ ↗
Phone	13026587581
Employees	149
Revenue	$0
Gross Profit	$0
Net Income	-$38.3M
Free Cash Flow	-$159.0M
Total Assets	$219.8M
Total Liabilities	$54.3M
Equity	$165.5M

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Kyverna Therapeutics, Inc. is a publicly traded company under the ticker symbol KYTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.